Xellia Pharmaceuticals is a global specialty pharmaceutical company headquartered in Copenhagen, Denmark. Established in 2008, Xellia specializes in the development, manufacturing, and commercialization of anti-infective treatments, primarily antibiotics, that address serious and often life-threatening infections. The company has a robust portfolio of both established and novel antibiotics, which are sold to more than 100 countries worldwide.

Xellia's products target a range of infections, including respiratory tract, skin and soft tissue, abdominal, and urinary tract infections, as well as sepsis. Xellia operates across seven production facilities in Europe and China, ensuring a reliable and efficient supply of high-quality antibiotics. They have research and development centers in Denmark and China, which focus on the development of new antibiotics and the improvement of existing products.

To strengthen its global presence and expand its product portfolio, Xellia has established several noteworthy subsidiaries and partnerships. In 2013, the company acquired a production facility in North Carolina, USA, further strengthening its presence in the United States. Additionally, Xellia has entered joint ventures with local partners in China, allowing it to access the Chinese market and collaborate on research and development projects.

As a leading player in the anti-infective market, Xellia holds a strong market position globally. Its products are highly regarded by healthcare professionals, and the company has built enduring partnerships with hospitals, governments, and pharmaceutical wholesalers across the world. With a reputation for quality and reliability, Xellia competes with other major pharmaceutical companies in the anti-infective sector.

In recent years, Xellia has undergone significant growth and development. In 2018, the company was acquired by Novo Holdings, a Danish investment firm, which provided the financial resources to expand its product portfolio and invest further in research and development. This acquisition marked a major milestone for Xellia, ensuring its long-term growth and sustainability.

As of the latest available information, Xellia continues to innovate and expand its portfolio while maintaining its commitment to providing high-quality anti-infective treatments. With a strong global presence and partnership network, the company remains dedicated to addressing the urgent healthcare needs associated with infectious diseases